Related Experiment Video
Updated: Jul 8, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.9K
Progesterone Hypersensitivity: The Utility of a Janus Kinase Inhibitor for Recurrent Erythema Multiforme
Andrew Claffey1, Melanie Evans2, Melissa Mauskar3
1Department of Obstetrics and Gynecology, UT Southwestern Medical Center, Dallas, Texas.
Journal of Pediatric and Adolescent Gynecology
|December 19, 2023
Summary
Progestogen hypersensitivity (PH) is a rare immune condition triggered by progesterone. This case report highlights a novel treatment approach using Janus kinase inhibitors for severe cyclical eruptions when hormonal therapy fails.
Area of Science:
- Immunology
- Endocrinology
- Dermatology
Background:
- Progestogen hypersensitivity (PH) is an uncommon immune response to progesterone during the luteal phase.
- The condition presents with a diverse clinical spectrum, complicating diagnosis.
Observation:
- A 14-year-old female experienced recurrent monthly oral mucositis and palmar erythema multiforme-like lesions.
- A comprehensive 2-year multidisciplinary workup and various medical therapies were administered.
Findings:
- The pathophysiology of PH is intricate due to progesterone's involvement in multiple biochemical pathways.
- Cyclical eruptions associated with PH can be managed with various therapeutic modalities.
Implications:
- Janus kinase (JAK) inhibitors are proposed as an effective treatment for PH when hormonal management is insufficient.
- Increased literature on PH prevalence suggests a growing recognition of this condition.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K